Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Hospital Universitario 12 de Octubre clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine and the EU Clinical Trials Information System (CTIS) — current trials in our Spain, Italy, Sweden and EU (CTIS) registers with Hospital Universitario 12 de Octubre as lead sponsor. Synced 14 Nov 2026
8Current trials
5Recruiting now
1Drug in these trials
4Trial registers
At a glance

Hospital Universitario 12 de Octubre is the lead sponsor of 8 current clinical trials in our Spain, Italy, Sweden and EU (CTIS) registers. 5 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Cannabidiol. The most-studied condition is Atrial Fibrillation.

ClinicalTrials.gov trials by status

  • Recruiting571%
  • Not yet open229%

Trials by phase

  • Not applicable457%
  • Observational343%
01

Clinical trials sponsored by Hospital Universitario 12 de Octubre

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Prognostic Model of Postnatal Circulation in Pulmonary Atresia-critical Stenosis With Intact Ventricular Septum
NCT07095829 · ClinicalTrials.gov ↗ · Pulmonary Atresia With Intact Ventricular Septum, Congenital Heart Disease, Fetal Cardiac Disorder
Observational Recruiting 2024-02 Spain, Sweden
Wide-Antral Pulmonary Vein Isolation in Atrial Fibrillation Ablation with a Single-shot Technique (WIDER-PVI)
NCT06698159 · ClinicalTrials.gov ↗ · Atrial Fibrillation, Atrial Fibrillation (Paroxysmal)
Not applicable Recruiting 2024-11 Spain, Italy
Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
NCT06896266 · ClinicalTrials.gov ↗ · Arrhythmia, Cardiomyopathy, Arrhythmia-induced Cardiomyopathy (AiCM)
Observational Recruiting 2024-12 Spain
Implementation of Biomarker-Based Care for mTBI - IMPACTS-BRAINI Study
NCT07311486 · ClinicalTrials.gov ↗ · Mild Traumatic Brain Injury (mTBI)
Observational Recruiting 2025-07 Spain
Clinical Trial for the Evaluation of Customized 3D Printed NIV Nasal Masks in Premature Infants
NCT06224816 · ClinicalTrials.gov ↗ · Premature Lungs
Not applicable Recruiting 2024-04 Spain
Intraventricular Hemorrhage in Kangaroo Care vs. Incubator Care
NCT07473882 · ClinicalTrials.gov ↗ · Kangaroo Care, Premature Infant, IVH- Intraventricular Hemorrhage
Not applicable Not yet open 2027-01 Spain
AI-Assisted Remote Monitoring for Patients With or at Risk of Malignant Bowel Obstruction
NCT07931989 · ClinicalTrials.gov ↗ · Malignant Bowel Obstruction, Intestinal Obstruction
Not applicable Not yet open 2026-11 Spain

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Hospital Universitario 12 de Octubre in the EU trials register (CTIS)

1 trial

Authorised or ongoing trials in the EU Clinical Trials Information System with Hospital Universitario 12 de Octubre as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

StudyPhaseStatusCountries
Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
2023-504439-42-03 · CTIS ↗ · Behavioral Disciplines and Activities
Phase 2 Authorised Spain
03

Drugs in Hospital Universitario 12 de Octubre trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

04

Conditions in Hospital Universitario 12 de Octubre trials

15 conditions
Atrial Fibrillation1Atrial Fibrillation (Paroxysmal)1Arrhythmia1Cardiomyopathy1Arrhythmia-induced Cardiomyopathy (AiCM)1Pulmonary Atresia With Intact Ventricular Septum1Congenital Heart Disease1Fetal Cardiac Disorder1Mild Traumatic Brain Injury (mTBI)1Kangaroo Care1Premature Infant1IVH- Intraventricular Hemorrhage1Malignant Bowel Obstruction1Intestinal Obstruction1Premature Lungs1
05

By trial register

RegisterTrialsRecruiting
Clinical trials in Spain75
Clinical trials in Italy11
Clinical trials in Sweden11
EU register (CTIS)1—

A trial with sites in more than one country appears in each of those registers.

06

Other sponsors in Atrial Fibrillation

SponsorTrials
Yonsei University12
Ottawa Heart Institute Research Corporation8
Biosense Webster7
Boston Scientific Corporation6
Volta Medical5
China National Center for Cardiovascular Diseases5
Population Health Research Institute4
Medtronic Cardiac Ablation Solutions4
Karolinska Institutet4
Insel Gruppe AG, University Hospital Bern4

Sponsors with the most current trials registered for this condition.

07

Questions about Hospital Universitario 12 de Octubre trials

How many clinical trials does Hospital Universitario 12 de Octubre sponsor?

Hospital Universitario 12 de Octubre is the lead sponsor of 7 current trials on ClinicalTrials.gov in our Spain, Italy and Sweden registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 14 November 2026. Completed and withdrawn studies are not counted.

Are Hospital Universitario 12 de Octubre trials recruiting?

Yes. 5 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hospital Universitario 12 de Octubre testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Cannabidiol (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 14 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.